VWA
MDGL icon

VSM Wealth Advisory’s Madrigal Pharmaceuticals MDGL Stock Holding History

VSM Wealth Advisory’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.2K Sell
60
-40
-40% -$20.5K 0.01% 258
2026
Q1 		$6.46K Buy
+100
New +$47.8K ﹤0.01% 395
2025
Q3 		– Sell
-280
Closed -$84.7K – 480
2025
Q2 		$84.7K Buy
280
+205
+273% +$61.1K 0.03% 153
2025
Q1 		$24.8K Buy
+75
New +$24.6K 0.01% 257

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VSM Wealth Advisory's MDGL Position: Q2 2026 in Review

VSM Wealth Advisory reduced its Madrigal Pharmaceuticals (MDGL) stake by 40% in Q2 2026, selling an estimated $20.5K and leaving 60 shares worth $32.2K. The position accounts for 0.01% of the portfolio, ranked #258.

VSM Wealth Advisory first reported a position in MDGL in Q1 2025 and has held it in 4 quarters since. The position peaked at $84.7K in Q2 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • VSM Wealth Advisory held 60 shares of Madrigal Pharmaceuticals worth $32.2K as of Q2 2026.
  • VSM Wealth Advisory sold 40 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $20.5K.
  • Madrigal Pharmaceuticals made up 0.01% of VSM Wealth Advisory's portfolio in Q2 2026, its #258 holding.
  • VSM Wealth Advisory first reported a position in Madrigal Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • VSM Wealth Advisory's Madrigal Pharmaceuticals position peaked at $84.7K in Q2 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on VSM Wealth Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.